Pellegrini R, Centis F, Martignone S, Mastroianni A, Tagliabue E, Tosi E, Ménard S, Colnaghi M I
Division of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Cancer Immunol Immunother. 1991;34(1):37-42. doi: 10.1007/BF01741322.
In this work a new monoclonal antibody (mAb), designated MGR1, which recognizes the epidermal growth factor receptor (EGF-R) binding site, is described. The main characteristic of this mAb is its ability to discriminate between cells that express normal levels of EGF-R from cells with overexpression, the detectability threshold by immunocytochemical tests being 5 x 10(4) receptors/cell of 10 microns diameter. MGR1 was found to inhibit EGF binding on the relevant target cells, and vice versa its binding was inhibited by EGF, which indicated that MGR1 recognizes the EGF receptor binding site. MGR1 exerted an inhibitory effect on both the in vitro and in vivo growth of cells with EGF-R overexpression, but had no effect on cells with a normal expression of the receptor. Tumour growth inhibition in athymic mice was also obtained on already implanted tumours. MGR1 therefore seems to be an adequate reagent for the development of immunotherapeutical approaches suitable for the treatment of tumours with EGF-R overexpression.
在本研究中，描述了一种新的单克隆抗体（mAb），命名为MGR1，它可识别表皮生长因子受体（EGF-R）结合位点。该单克隆抗体的主要特性是能够区分表达正常水平EGF-R的细胞与过表达该受体的细胞，免疫细胞化学检测的可检测阈值为直径10微米的细胞中5×10⁴个受体/细胞。发现MGR1可抑制相关靶细胞上的EGF结合，反之，其结合也受到EGF的抑制，这表明MGR1识别EGF受体结合位点。MGR1对EGF-R过表达的细胞的体外和体内生长均产生抑制作用，但对受体正常表达的细胞无影响。在无胸腺小鼠中，对已植入的肿瘤也观察到了肿瘤生长抑制作用。因此，MGR1似乎是开发适用于治疗EGF-R过表达肿瘤的免疫治疗方法的合适试剂。
